Ali Asif — SEC Form 4 filings

SEC reporting owner CIK 1921163. 13 Form 4 filings on record with FilingPulse; latest filed 2026-04-21.

Transaction summary — filings shown

Covers all 13 filings on record, filed 2024-01-18 to 2026-04-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Protagonist Therapeutics, Inc (PTGX)Chief Financial Officer1316 legs · 151,507 sh · $10,286,00423

Form 4 filings — Ali Asif

FiledFormIssuerReported transactionsSource
2026-04-214Protagonist Therapeutics, Inc (PTGX)Sale (S): 1,750 @ $105.47EDGAR
2026-03-274Protagonist Therapeutics, Inc (PTGX)Option exercise (M): 19,500 @ $19.19 · Option exercise (M): 5,265 @ $12.17 · Sale (S): 24,765 @ $104.24 · Option exercise (M): 19,500 (derivative) @ $0 · Option exercise (M): 5,265 (derivative) @ $0EDGAR
2026-01-274Protagonist Therapeutics, Inc (PTGX)Option exercise (M): 16,000 @ $19.19 · Option exercise (M): 12,000 @ $12.17 · Sale (S): 28,000 @ $83.13 · Sale (S): 18,203 @ $83.14 · Option exercise (M): 16,000 (derivative) @ $0 · Option exercise (M): 12,000 (derivative) @ $0EDGAR
2026-01-214Protagonist Therapeutics, Inc (PTGX)Sale (S): 8,588 @ $82.48EDGAR
2026-01-064Protagonist Therapeutics, Inc (PTGX)Grant/award (A): 25,600 @ $0 · Grant/award (A): 32,000 (derivative) @ $0EDGAR
2025-04-234Protagonist Therapeutics, Inc (PTGX)Sale (S): 1,756 @ $46EDGAR
2025-03-144Protagonist Therapeutics, Inc (PTGX)Option exercise (M): 15,203 @ $12.17 · Option exercise (M): 9,700 @ $19.19 · Sale (S): 24,903 @ $58.73 · Option exercise (M): 15,203 (derivative) @ $0 · Option exercise (M): 9,700 (derivative) @ $0EDGAR
2025-01-174Protagonist Therapeutics, Inc (PTGX)Sale (S): 1,317 @ $0 · Sale (S): 2,601 @ $0EDGAR
2025-01-064Protagonist Therapeutics, Inc (PTGX)Grant/award (A): 31,779 @ $0 · Grant/award (A): 38,520 (derivative) @ $0EDGAR
2024-09-134Protagonist Therapeutics, Inc (PTGX)Sale (S): 2,203 @ $44.59 · Option exercise (M): 6,000 @ $19.19 · Option exercise (M): 6,000 @ $12.17 · Sale (S): 12,000 @ $44.47 · Option exercise (M): 6,000 (derivative) @ $0 · Option exercise (M): 6,000 (derivative) @ $0EDGAR
2024-04-194Protagonist Therapeutics, Inc (PTGX)Sale (S): 1,234 @ $25.11EDGAR
2024-03-014Protagonist Therapeutics, Inc (PTGX)Sale (S): 7,850 @ $30.61 · Sale (S): 2,089 @ $31 · Option exercise (M): 12,000 @ $12.17 · Sale (S): 12,000 @ $32.22 · Sale (S): 2,248 @ $32.33 · Option exercise (M): 12,000 (derivative) @ $0EDGAR
2024-01-184Protagonist Therapeutics, Inc (PTGX)Tax withholding (F): 1,452 @ $24.63EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1921163 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →